Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 69.3267
- Book/Share 43.6271
- PB 7.1674
- Debt/Equity 0.6749
- CurrentRatio 0.7996
- ROIC 0.295
- MktCap 1390466076007.6992
- FreeCF/Share 12.6317
- PFCF 24.7484
- PE 13.6097
- Debt/Assets 0.2412
- DivYield 0.0248
- ROE 0.6096
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NVO | Jefferies | Underperform | Hold | -- | -- | Feb. 12, 2026 |
| Initiation | NVO | Citigroup | -- | Neutral | -- | -- | Jan. 27, 2026 |
| Downgrade | NVO | Argus | Buy | Hold | -- | -- | Dec. 8, 2025 |
| Resumed | NVO | Jefferies | -- | Underperform | -- | -- | Oct. 27, 2025 |
| Upgrade | NVO | HSBC Securities | Hold | Buy | -- | -- | Oct. 1, 2025 |
| Downgrade | NVO | Morgan Stanley | Equal Weight | Underweight | -- | $47 | Sept. 29, 2025 |
| Upgrade | NVO | Berenberg | Hold | Buy | -- | -- | Sept. 17, 2025 |
| Upgrade | NVO | Rothschild & Co Redburn | Neutral | Buy | -- | -- | Sept. 16, 2025 |
| Upgrade | NVO | Bernstein | Market Perform | Outperform | -- | -- | Sept. 9, 2025 |
| Upgrade | NVO | BNP Paribas Exane | Underperform | Neutral | -- | $54 | Aug. 13, 2025 |
News
Novo Nordisk: The Possible Upside
Published: February 17, 2026 by: Seeking Alpha
Sentiment: Neutral
Weight loss treatments provider Novo Nordisk might have experienced a sharp stock decline after disappointing 2025 results and 2026 outlook, but it has seen an impressive bounce back since. While the expected financial weakness is a real downer, there's a possibility of a sales surprise this year considering the company's recent vigorous actions as well as promising launches. NVO's forward P/E has fallen so low now that further upside looks unmistakable. This is especially true as the company is expected to return to improved financial health from 2027.
Read More
Novo Nordisk's Wegovy Weight Loss Shot Approved at Higher Dose in EU
Published: February 17, 2026 by: WSJ
Sentiment: Positive
Patients on the higher dose of 7.2 milligrams for about 18 months lost 21% of their body weight on average, a study found.
Read More
EU approves higher dose of Novo's Wegovy
Published: February 17, 2026 by: Reuters
Sentiment: Positive
The European Commission has approved a higher dose of Novo Nordisk's popular weight-loss drug Wegovy, the Danish drugmaker said on Tuesday.
Read More
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Negative
Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.
Read More
Novo Nordisk plans Wegovy vials amid obesity-drug competition
Published: February 12, 2026 by: Proactive Investors
Sentiment: Positive
Novo Nordisk (NYSE:NVO) announced that it is planning to introduce its weight-loss medication Wegovy in vials. “We are exploring various device presentations for Wegovy, including vials—some are launching this year, others are coming in the future,” the company said.
Read More
Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market
Published: February 12, 2026 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S (NYSE: NVO) plans to start selling its blockbuster obesity drug Wegovy in vials, marking its latest effort to strengthen its position against rival Eli Lilly and Co. (NYSE: LLY) as competition intensifies in the fast-growing weight-loss market.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: February 11, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 11 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Read More
Novo Nordisk faces a defining year in the obesity drug market. It's off to a dramatic start
Published: February 11, 2026 by: CNBC
Sentiment: Neutral
Novo Nordisk CEO Mike Doustdar has a plan to steer the company through what's been described as a “show me” year. The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share in the blockbuster weight loss drug market.
Read More
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Published: February 11, 2026 by: CNBC
Sentiment: Positive
Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments. Doustdar said he doesn't expect Medicare access to obesity treatments, expected later this year, to open up overnight.
Read More
Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook?
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Negative
NVO expects to face a shaky 2026 as Ozempic and Wegovy sales slow down and guidance signals decline despite a milestone oral Wegovy launch.
Read More
Novo Nordisk: How Low Is Too Low? (Downgrade, Technical Analysis)
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk A/S has seen its stock fall sharply, driven by a dramatic slowdown in EPS growth and weak 2026 guidance. A large drop was justified. This article looks at whether it could be overdone. Technical analysis suggests potential support at $36.80 and $29, which would be back to 2018-2020 levels. The company has grown significantly since then.
Read More
Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Neutral
Keeping my Buy rating on Novo Nordisk A/S despite a disappointing negative 2026 sales guidance amid fierce competition from Eli Lilly and compounders. NVO's Wegovy pill launch shows encouraging early uptake, with supply chain issues resolved and direct channel traction building. I reckon management's conservative 2026 outlook aims to reset expectations, positioning NVO for a potential re-rating as execution potentially improves from 2027.
Read More
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Novo Nordisk, Hims & Hers Health Shares React to Lawsuit
Published: February 09, 2026 by: Schaeffers Research
Sentiment: Negative
Pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) revealed today it is pursing legal action against Hims & Hers Health Inc (NYSE:HIMS) for alleged patent infringement, after the telehealth giant introduced a weight-loss pill with the same active ingredient as its Wegovy drug -- priced at $149 -- at a much lower starting price of $49.
Read More
Novo Nordisk's latest salvo against Hims & Hers—a patent-infringement lawsuit—shows the fierce maneuvering over the booming obesity-drug market
Published: February 09, 2026 by: WSJ
Sentiment: Neutral
The Danish drugmaker's patent lawsuit is the company's latest effort to shore up its place in the booming weight-loss drug market.
Read More
Hims & Hers Stock Plunges While Novo Nordisk Gains as Weight-Loss Drug Wars Take New Turn
Published: February 09, 2026 by: Investopedia
Sentiment: Neutral
Hims & Hers Health shares are tumbling after a major blow to its weight-loss lineup.
Read More
FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
Published: February 09, 2026 by: CNBC
Sentiment: Negative
The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients. In a letter to Novo dated Feb. 5, the FDA requested that the drugmaker take immediate action to address the violations, which could include ceasing all ads containing misleading claims.
Read More
HIMS Slides 25% After NVO Sues Company Over Generic GLP-1 Pills
Published: February 09, 2026 by: Schwab Network
Sentiment: Negative
Legal issues hits Hims & Hers (HIMS). Novo Nordisk (NVO) filed a lawsuit against the company over allegedly selling unapproved Wegovy and Ozempic weight loss drugs.
Read More
FDA says Novo's obesity pill TV Ad is false or misleading
Published: February 09, 2026 by: Reuters
Sentiment: Negative
The Food and Drug Administration said a television advertisement for Novo Nordisk's weight loss pill is "false or misleading", according to a letter dated February 5.
Read More
Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
NVO shares swing sharply after fears over cheap compounded GLP-1 pills, before FDA action and a Hims retreat spark a sharp rebound.
Read More
Dr. Scott Gottlieb on Novo Nordisk vs. Hims & Hers: We have a drug approval process for a reason
Published: February 09, 2026 by: CNBC Television
Sentiment: Neutral
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the fight between Novo Nordisk and Hims & Hers over GLP-1 drugs, immunization policies in the U.S., and more.
Read More
Novo Nordisk: The Selloff Is A Blessing In Disguise
Published: February 06, 2026 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk A/S remains a Strong Buy despite a sharp 2026 outlook-driven selloff, with current pricing reflecting excessive market pessimism. NVO faces near-term headwinds from U.S. pricing pressure, patent expirations, and manufacturing ramp-up delays, but underlying free cash flow and profitability remain robust. The Wegovy pill's rapid uptake and first-mover advantage, alongside CagriSema's promising efficacy, position NVO for long-term GLP-1 market leadership.
Read More
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Published: February 05, 2026 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 5 February 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk.
Read More
LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic
Published: February 05, 2026 by: Schwab Network
Sentiment: Positive
After Eli Lilly (LLY) posted earnings that outshined Novo Nordisk's (NVO) decelerating growth, Scott Zari feels comfortable calling Eli Lilly the dominant winner in the weight loss drug race. While he notes Novo Nordisk's pill as "important" to consumers, it's Eli Lilly's injectable he sees continuing to lead GLP-1 momentum.
Read More
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding' Over Cheaper Wegovy Version
Published: February 05, 2026 by: WSJ
Sentiment: Negative
Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan.
Read More
Novo Nordisk CEO: Hims' $49 compounded Wegovy pill a 'waste' of money
Published: February 05, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers Health was launching a cut-price version of Novo's blockbuster Wegovy weight loss pill.
Read More
Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
Published: February 05, 2026 by: Reuters
Sentiment: Negative
Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an introductory price of $49 per month.
Read More
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
Published: February 05, 2026 by: Market Watch
Sentiment: Positive
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Read More
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Published: February 05, 2026 by: CNBC
Sentiment: Negative
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock dropped on the news, while Hims shares jumped.
Read More
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
Published: February 05, 2026 by: MarketBeat
Sentiment: Neutral
The first week of February 2026 will be remembered as the day the pharmaceutical sector's most famous partnership officially dissolved. For years, Eli Lilly and Company NYSE: LLY and Novo Nordisk A/S NYSE: NVO traded in lockstep, their stock charts nearly identical as they raced to supply the world with weight-loss medicines.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406